Straits Times Index
3,290.79 +8.74 (+0.27%) Nikkei
38,405.66 +470.90 (+1.24%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,173.98 +26.95 (+0.33%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,312.01 -27.06 (-2.02%)
AMGN Jan 2025 160.000 put
| Previous close | 1.1000 |
| Open | 1.1000 |
| Bid | 0.5600 |
| Ask | 2.3000 |
| Strike | 160.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.1000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 212 |
- Reuters
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
ZacksWhat's in the Cards for Amgen (AMGN) This Earnings Season?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
